✦ LIBER ✦

Significance of immune response to enzyme-replacement therapy for patients with a lysosomal storage disorder

✍ Scribed by Doug A. Brooks; Revecca Kakavanos; John J. Hopwood

Book ID: 116757782
Publisher: Elsevier Science
Year: 2003
Tongue: English
Weight: 119 KB
Volume: 9
Category: Article
ISSN: 1471-4914
DOI: 10.1016/j.molmed.2003.08.004

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Immune Response to Enzyme Replacement Th

Immune Response to Enzyme Replacement Therapy in Lysosomal Storage Disorder Patients and Animal Models

✍ Doug A. Brooks 📂 Article 📅 1999 🏛 Elsevier Science 🌐 English ⚖ 206 KB

142. A systematic approach towards ident

142. A systematic approach towards identifying and treating delayed infusion reactions to enzyme replacement therapy in patients with lysosomal storage disorders

✍ Jeanine Utz; Brenda Diethelm-Okita; Chester B. Whitley 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 41 KB

The Mainz Severity Score Index: a new in

The Mainz Severity Score Index: a new instrument for quantifying the Anderson–Fabry disease phenotype, and the response of patients to enzyme replacement therapy

✍ C Whybra; C Kampmann; F Krummenauer; M Ries; E Mengel; E Miebach; F Baehner; K K 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 122 KB

Development of a panel of highly sensiti

Development of a panel of highly sensitive, equivalent assays for detection of antibody responses to velaglucerase alfa or imiglucerase enzyme replacement therapy in patients with Gaucher disease

✍ Márcia Séllos-Moura; Samad Barzegar; Luying Pan; Philip Shi; Susan Oommen; Judit 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 289 KB

Adacolumn for selective leukocytapheresi

Adacolumn for selective leukocytapheresis as a non-pharmacological treatment for patients with disorders of the immune system: An adjunct or an alternative to drug therapy?

✍ Abbi R. Saniabadi; Hiroyuki Hanai; Yasuo Suzuki; Toshihide Ohmori; Koji Sawada; 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 661 KB

Inflammatory and/or autoimmune diseases like ulcerative colitis (UC) or Crohn's disease (CD) are debilitating chronic disorders that poorly respond to pharmacological interventions. Further, drug therapy has adverse effects that add to disease complications. The current thinking is that disorders li

A randomized, open-label study to compar

A randomized, open-label study to compare the efficacy and safety of AT1001 and enzyme replacement therapy (ERT) in patients with Fabry disease and AT1001-responsive GLA mutations, who were previously treated with ERT

✍ Mathews Adera; Allison Gladden; Pol Boudes 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 60 KB